The IBD drug pipeline-ready to deliver?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 24989095.
- Also identified by DOI 10.1038/ajg.2014.179.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The study of modified-release phosphatidylcholine in this issue of the American Journal of Gastroenterology by Karner et al. is a substantial step forward for a mucosal barrier agent in inflammatory bowel disease (IBD). It is the first agent in a novel class to demonstrate clinical efficacy in a phase 2 study. There are a number of new agents with new mechanisms of action that are rapidly advancing through the IBD drug development pipeline. This article reviews the promising candidates and mechanisms of action in late-phase trials in IBD.
Medical subject headings
- Colitis, Ulcerative
- Phosphatidylcholines